title: 2016 European guideline on Mycoplasma genitalium infections.
abstract: Mycoplasma genitalium infection contributes to 10-35% of non-chlamydial non-gonococcal urethritis in men. In women, M. genitalium is associated with cervicitis and pelvic inflammatory disease (PID). Transmission of M. genitalium occurs through direct mucosal contact. Asymptomatic infections are frequent. In women, symptoms include vaginal discharge, dysuria or symptoms of PID - abdominal pain and dyspareunia. In men, urethritis, dysuria and discharge predominates. Besides symptoms, indication for laboratory test is a high-risk sexual behaviour. Diagnosis is achievable only through nucleic acid amplification testing (NAAT). If available, NAAT diagnosis should be followed with an assay for macrolide resistance. Therapy for M. genitalium is indicated if M. genitalium is detected or on an epidemiological basis. Doxycycline has a low cure rate of 30-40%, but does not increase resistance. Azithromycin has a cure rate of 85-95% in macrolide susceptible infections. An extended course appears to have a higher cure rate. An increasing prevalence of macrolide resistance, most likely due to widespread use of azithromycin 1 g single dose without test of cure, is drastically decreasing the cure rate. Moxifloxacin can be used as second-line therapy, but resistance is increasing. Uncomplicated M. genitalium infection should be treated with azithromycin 500 mg on day one, then 250 mg on days 2-5 (oral), or josamycin 500 mg three times daily for 10 days (oral). Second line treatment and treatment for uncomplicated macrolide resistant M. genitalium infection is moxifloxacin 400 mg od for 7-10 days (oral). For third line treatment of persistent M. genitalium infection after azithromycin and moxifloxacin doxycycline 100 mg two times daily for 14 days can be tried and may cure 30%. Pristinamycin 1 g four times daily for 10 days (oral) has a cure rate of app. 90%. Complicated M. genitalium infection (PID, epididymitis) is treated with moxifloxacin 400 mg od for 14 days.
authors: Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark. jsj@ssi.dk.
authors: J S
authors: JS
authors: Jensen
authors: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
authors: M
authors: M
authors: Cusini
authors: Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology, Moscow, Russia.
authors: M
authors: M
authors: Gomberg
authors: Olafia Clinic, Oslo University Hospital, Institute of Medicine, University of Oslo, Oslo, Norway.
authors: H
authors: H
authors: Moi
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use*; D008297:Male; D009175:Mycoplasma Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D045704:Mycoplasma genitalium / Q000302:isolation & purification*
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides